In Vivo MRI-CEST Tumor pH Imaging Detects Resistance to Proton Pump Inhibitors in Human Prostate Cancer Murine Models

• Published in: Cancers Vol. 14; no. 19; p. 4916
• Main Authors: Irrera, Pietro, Consolino, Lorena, Roberto, Miriam, Capozza, Martina, Dhakan, Chetan, Carella, Antonella, Corrado, Alessia, Villano, Daisy, Anemone, Annasofia, Navarro-Tableros, Victor, Bracesco, Martina, Dastrù, Walter, Aime, Silvio, Longo, Dario Livio
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2022; MDPI
• Subjects: Acidification; Acidity; Acidosis; Amiloride; Animal models; Biomarkers; Body weight; Breast cancer; Cancer; Cancer therapies; Cell culture; Cell viability; Diagnosis; Diagnostic imaging; Dosage and administration; Drug resistance; Drug therapy; Enzymes; Experiments; Hypoxia; Immunotherapy; Magnetic resonance imaging; Metabolism; Methods; Omeprazole; Oncology, Experimental; pH effects; Positron emission tomography; Prostate cancer; Proton pump inhibitors; Respiration; Toxicity; Tumor cell lines; Tumor microenvironment; Tumors; Italy; St Louis Missouri; United States > US
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14194916

The tumor microenvironment acidification confers treatment resistance; therefore, the interference with pH regulating systems is considered a new therapeutic strategy. In this study, two human prostate cancer cell lines, PC3 and LNCaP, have been treated in vitro with proton pump inhibitors (PPIs), namely Lansoprazole, Esomeprazole (V-ATPases-inhibitors), Cariporide, and Amiloride (NHE1-inhibitors). The cell viability and pH were assessed at several drug concentrations either at normoxic or hypoxic conditions. Since Esomeprazole showed the highest toxicity towards the PC3 cancer cells compared to LNCaP ones, athymic nude mice bearing subcutaneous or orthotopic PC3 tumors were treated with Esomeprazole (dose: 2.5 mg/kg body weight) for a period of three weeks—and tumor growth was monitored. MRI-CEST tumor pH imaging with Iopamidol was performed upon treatment at 3 h, 1 week (in combination with FDG-PET), and after 2 weeks for evaluating acute, early, and late responses. Although acute tumor pH changes were observed in vivo, long-term studies on both PC3 prostate cancer models did not provide any significant change in tumor acidosis or tumor growth. In conclusion, this work shows that MRI-CEST tumor pH imaging is a valuable tool for assessing the in vivo treatment response to PPIs.